Answers are grounded in this paper and cite their sources.
Purpose Acromegaly causes chronic growth hormone and insulin-like growth factor-1 excess, which may promote thyroid proliferation. Whether acromegaly increases thyroid cancer and structural thyroid disease odds remains uncertain. So we aim to determine whether patients with acromegaly have higher odds of thyroid cancer and structural thyroid abnormalities than individuals without acromegaly. Methods PubMed, Embase, and Cochrane Library were searched from inception to March 2026. Observational comparative studies of patients with acromegaly and non-acromegaly comparators reporting thyroid outcomes were eligible. Case reports, case series, reviews, abstracts, overlapping populations and studies without comparative thyroid cancer data were excluded. Two reviewers independently screened records; 13 of 2,623 were included. Three reviewers independently extracted study characteristics, participant data, acromegaly criteria, thyroid cancer subtypes, nodular disease, volume, and biochemical outcomes. Risk of bias was assessed using ROBINS-E or JBI, and certainty was evaluated using GRADE. Results Thirteen studies included 719,090 participants; 2,674 had acromegaly. Acromegaly was associated with higher odds of overall thyroid cancer (OR 4.00, 95% CI 2.21–7.24), papillary carcinoma (OR 2.81, 95% CI 1.60–4.91) and thyroid nodular disease (OR 2.60, 95% CI 1.80–3.76). Thyroid volume was greater in acromegaly (MD 12.57 mL, 95% CI 5.27–19.86). Follicular thyroid carcinoma, free thyroxine and thyroid-stimulating hormone did not differ significantly. Conclusion Acromegaly was associated with thyroid cancer and structural thyroid disease, but not with significant differences in routine thyroid function markers.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: